Germany-based Evonik’s Venture Capital group has invested in China-based Jland Biotech; under the agreement, Evonik will market Jland's vegan collagen for skin care, anti-aging and hydrating creams, among other cosmeceutical, bioactive applications.
The collagen will be "manufactured in collaboration with Jland," according to Evonik, and will be commercially launched later in 2024.
The new collagen technology, which is fully registered with the Vegan Society, will complement Evonik's existing Vecollage Fortify L vegan collagen.
Vecollage Fortify L is a recombinant collagen that reportedly positively impacts the skin's middle layer, the dermis, to prevent age-related degradation while also stimulating the skin’s own collagen production.
High tech ingredients such as these emerging biotech collagens feed into consumers' growing demand for dermatologically sound beauty products.
Evonik argues that bacteria- or yeast-derived non-animal collagen produced via controlled fermentation-based processes "is easier to formulate and better absorbed by the skin than animal-derived collagen."
Furthermore, collagen produced via this process reportedly "has low immunogenicity and batch-to-batch variability and is highly reproducible."
“Evonik’s life sciences division is using its biotechnology platform to leverage the expertise of its partners and collaborate on precision biosolutions," said Johann-Caspar Gammelin, president of the Nutrition & Care division. "We welcome Jland to our partner network. Together with our expertise in active ingredients and delivery systems, we are creating a world-leading portfolio of non-animal derived collagen.”
“We value Jland’s outstanding approach to innovation and look forward to helping our customers develop the science-based, sophisticated beauty solutions that consumers worldwide are looking for,” said Yann d'Hervé, head of Evonik's Care Solutions business line.
